Advanced pancreatic cancer: Flourishing novel approaches in the era of biological therapy

Oncologist

Volumn 19, Issue 9, 2014, Pages 937-950

  Chiu, Joanne W ^a   Wong, Hilda ^a   Leung, Roland ^a   Pang, Roberta ^a,b   Cheung, Tan To ^a   Fan, Sheung Tat ^a,b   Poon, Ronnie ^a,b   Yau, Thomas ^a,b  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Advanced pancreatic cancer; Biological therapy; Gemcitabine; Targeted therapy

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CLIVATUZUMAB TETRAXETAN Y 90; ERLOTINIB; EVOFOSFAMIDE; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; IRINOTECAN; LONAFARNIB; MASITINIB; N (6, 7 DIHYDRO 6 OXO 5H DIBENZ [B, D] AZEPIN 7 YL) 2, 2 DIMETHYL N' (2, 2, 3, 3, 3 PENTAFLUOROPROPYL) PROPANEDIAMIDE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PELAREOREP; PIMASERTIB; REFAMETINIB; RIGOSERTIB; SELUMETINIB; SORAFENIB; TERTOMOTIDE; TIPIFARNIB; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; DEOXYCYTIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ANGIOGENESIS; ARTICLE; BIOLOGICAL THERAPY; GENE MUTATION; HUMAN; LETHALITY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; CANCER STAGING; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY;

DEOXYCYTIDINE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84906976007     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0131     Document Type: Article

References (123)

1. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
2. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
3. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-1703.
4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25: 1960-1966.
5. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801-1806.
6. Almoguera C, Shibata D, Forrester K et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-554.
7. Hezel AF, Kimmelman AC, Stanger BZ et al. Genetics and biology of pancreatic ductal adeno-carcinoma. Genes Dev 2006;20:1218-1249.
8. Schutte M, Hruban RH, Geradts J et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreaticcarcinomas. Cancer Res1997; 57:3126-3130.
9. Caldas C, Hahn SA, da Costa LT et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreaticadenocarcinoma. Nat Genet 1994;8:27-32.
10. Goggins M, Schutte M, Lu J et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-5364.
11. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-3652.
12. Cohen SJ, Ho L, Ranganathan S et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarci-noma. J Clin Oncol 2003;21:1301-1306.
13. Macdonald JS, McCoy S, Whitehead RP et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest Oncology Group (SWOG 9924) study. Invest New Drugs 2005;23:485-487.
14. Van Cutsem E, Van de Velde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22: 1430-1438.
15. Lersch C, van Cutsem E, Amado R et al. Randomized phase II study of sch 66336 and gemcitabine in the treatment of metastatic adeno-carcinoma of the pancreas. Proc Am Soc Clin Oncol 2001;20:608a.
16. Morioka CY, Machado MC, Saito S et al. Suppression of invasion of a hamster pancreatic cancer cell line by antisense oligonucleotides mutation-matched to K-ras gene. In Vivo 2005;19: 535-538.
17. Réjiba S, Wack S, Aprahamian M et al. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007; 98:1128-1136.
18. Bodoky G, Timcheva C, Spigel DR et al. A phase II open-label randomized studyto assessthe efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 2012; 30:1216-1223.
19. Ko AH, Tempero MA, Bekaii-Saab TB et al. Dual mek/egfr inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (azd6244; arry-142886) plus erlotinib. J Clin Oncol 2013;31(suppl):4014a.
20. Tolcher AW, Bendell JC, Patnaik A et al. A phase ib study of the mek inhibitor gsk1120212 combined with gemcitabine in patients with solid tumors: Interim results. J Clin Oncol 2011;29:278a.
21. Infante JR, Somer BG, Park JO et al. A randomized, double-blind, placebo-controlled trial of trametinib, a mek inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. J Clin Oncol 2013; 31(Suppl 4):291a.
22. Collins MA, Bednar F, Zhang Y et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122:639-653.
23. Safran H, Steinhoff M, Mangray S et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001;24:496-499.
24. Lemoine NR, Hughes CM, Barton CM et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol 1992;166:7-12.
25. Yamanaka Y, Friess H, Kobrin MS et al. Coex-pression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-569.
26. Dong M, Nio Y, Guo KJ et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998;18(6B):4613-4619.
27. Tobita K, Kijima H, Dowaki S et al. Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 2003;11:305-309.
28. da Cunha Santos G, Dhani N, Tu D et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 2010;116:5599-5607.
29. Kulke MH, Blaszkowsky LS, Ryan DP et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007;25: 4787-4792.
30. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 2004;22: 2610-2616.
31. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605-3610.
32. Kim GP, Foster NR, Salim M et al. Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. J Clin Oncol 2011;29 (suppl):4030a.
33. Safran H, Iannitti D, Ramanathan R et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004;22:706-712.
34. Seo Y, Baba H, Fukuda T et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239-2245.
35. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28:3617-3622.
36. Van Cutsem E, Vervenne WL, Bennouna J et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-2237.
37. Spano JP, Chodkiewicz C, Maurel J et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet 2008;371:2101-2108.
38. Kindler HL, Ioka T, Richel DJ et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 2011;12:256-262.
39. Rougier P, Riess H, Manges R et al. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 2013;49:2633-2642.
40. Goncalves A, Gilabert M, Francois E et al. Baypan study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012;23: 2799-2805.
41. Deplanque G, Demarchi M, Hebbar M et al. Masitinib in nonresectable pancratic cancer: Results of a phase III randomized placebo-controlled trial. J Clin Oncol 2012;31(suppl 4):158a.
42. Tabernero J. The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 2007;5: 203-220.
43. Kindler HL, Gangadhar T, Karrison T et al. Final analysis of a randomized phase II study of bevacizumab and gemcitabine plus cetuximab or erlotinib in patients with advanced pancreatic cancer. J Clin Oncol 2008;26(suppl):4502a.
44. Starling N, Watkins D, Cunningham D et al. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol 2009;27:5499-5505.
45. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
46. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-518.
47. Bergmann U, Funatomi H, Yokoyama M et al. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles. Cancer Res 1995;55:2007-2011.
48. Freeman JW, Mattingly CA, Strodel WE. Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J Cell Physiol 1995;165:155-163.
49. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and g protein-coupled receptor signaling systems: A novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010;16:2505-2511.
50. Dimou AT, Syrigos KN, Saif MW. Novel agents for the treatment of pancreatic adenocarcinoma: Any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting, Chicago, IL, USA, June 4-8, 2010. J Pancreas 2010;11:324-327.
51. Philip PA, Goldman BH, Ramanathan RK et al. SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2010;28 (suppl 15):TPS223a.
52. Kindler HL, Richards DA, Stephenson J et al. A placebo-controlled, randomized phase II study of conatumumab (c) or amg 479 (a) or placebo (p) plus gemcitabine (g) in patients (pts) with metastatic pancreatic cancer (mpc). J Clin Oncol 2010;28: 4035a.
53. Fuchs CS, Azevedo SJ, Carrato A et al. A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (g) as first-line therapy for metastatic adenocarcinoma of the pancreas: The gamma trial. J Clin Oncol 2012;30:TPS4135a.
54. Amgen. Amgen announced termination of ganitumab phase 3 study for futility in metastatic pancreatic cancer. Available at http://www.amgen. com/media/media_pr_detail.jsp?releaseID5 1723925. Accessed April 27, 2014.
55. Javle MM, Varadhachary GR, Shroff RT et al. Phase I/II study of mk-0646, the humanized monoclonal igf-1 antibody in combination with gemcitabine or gemcitabine plus erlotinib for advanced pancreatic cancer. J Clin Oncol 2010;18(supp): 4039a.
56. Javle MM, Varadhachary GR, Fogelman DR et al. Randomized phase II study of gemcitabine (g) plusanti-igf-1rantibodymk-0646, gpluserlotinib(e) plus mk-0646 and g plus e for advanced pancreatic cancer. J Clin Oncol 2011;29:4026a.
57. Hanks BA, Holtzhausen A, Gimpel P et al. Effect of the loss of the type III TGFb receptorduringtumor progression on tumor microenvironment: Preclinical development of TGFb inhibition and TGFb-related biomarkers to enhance immunotherapy efficacy. J Clin Oncol 2012;30:10563a.
58. Ikushima H, Miyazono K. TGF beta signalling: A complex web in cancer progression. Nat Rev Cancer 2010;10:415-424.
59. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
60. Chow JY, Ban M, Wu HL et al. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2010;298:G275-G282.
61. Feng C, Yao R, Huang F et al. High level of PTEN expression is associated with low-grade liver metastasis and satisfactory patient survival in pancreatic cancer. Arch Med Res 2011;42:584-588.
62. Oettle H, Seufferiein T, Luger T et al. Final results of a phase I/II study in patients with pancreatic cancer, malignant melanoma, and colorectal carcinoma with trabedersen. J Clin Oncol 2012;30(supp):4034a.
63. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005;23:2078-2093.
64. Wolpin BM, Hezel AF, Abrams T et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-198.
65. Javle MM, Shroff RT, Xiong H et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies. BMC Cancer 2010;10:368.
66. Ma WW, Messersmith WA, Dy GK et al. Final resultsof aphasei studyof thecombinationof anovel cell cycle inhibitor on 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors. J Clin Oncol 2011;29(suppl):3101a.
67. Onconova Therapeutics. Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study, 2013. Available at http://investor.onconova.com/releasedetail.cfm?Relea-seID5814465. Accessed July 14, 2014.
68. Fortini ME. Notch signaling: The core pathway and its posttranslational regulation. Dev Cell 2009; 16:633-647.
69. O'Reilly EM, Smith LS, Bendell JC et al. Phase 1b of anticancer stem cell antibody omp-59r5 (anti-notch 2/3) in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic cancer. J Clin Oncol 2014;32(suppl 3): 220a
70. Gracian AC, Jameson MB, Grande E et al. A phase 1b study of the anticancer stem cell agent demcizumab and gemcitabine with or without paclitaxel protein bound particles in patients with pancreatic cancer. J Clin Oncol 2014;32(suppl 3): 279a.
71. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
72. Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87:161-167.
73. Moore MJ, Hamm J, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21: 3296-3302.
74. Toole BP, Slomiany MG. Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 2008;18:244-250.
75. Jacobetz MA, Chan DS, Neesse A et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62:112-120.
76. Hingorani SR, Harris WP, Beck JT et al. A phase 1b study of gemcitabine plus pegph20 (pegylated recombinant human hyaluronidase) in patients with stage iv previously untreated pancreatic cancer. J Clin Oncol 2013;31(suppl):4010a.
77. Snow AD, Bolender RP, Wight TN et al. Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells. Am J Pathol 1990;137:313-330.
78. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J 1997;11:51-59.
79. Sudha T, Phillips P, Kanaan C et al. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis 2012;29:431-439.
80. Lee DY, Lee SW, Kim SK et al. Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells. Pharm Res 2009;26: 2667-2676.
81. Hidalgo M, Maitra A. The hedgehog pathway and pancreatic cancer. N Engl J Med 2009;361: 2094-2096.
82. Thayer SP, di Magliano MP, Heiser PW et al. Hedgehog isan early andlatemediator of pancreatic cancer tumorigenesis. Nature 2003;425:851-856.
83. Olive KP, Jacobetz MA, Davidson CJ et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461.
84. Richards DA, Stephenson J, Wolpin BM et al. A phase Ib trial of ipi-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol 2012;30(Suppl 4):213a.
85. Infinity Pharmaceuticals. Infinity Reports Update From Phase 2 Study of Saridegib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer, 2012. Available at http://www.businesswire.com/ news/home/20120127005146/en/Infinity-Reports-Update-Phase-2-Study-Saridegib#.U8PymNhOV2s. Accessed April 27, 2014.
86. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9: 239-252.
87. Ryan DP, Reddy SG, Bahary N et al. Th-302 plus gemcitabine versus gemcitabine in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2012;31(suppl 4):325a.
88. Hosein PJ, de Lima Lopes GJr., Pastorini VH et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2013;36:151-156.
89. Xie X, Xia W, Li Z et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 2007;12:52-65.
90. Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009;106:7155-7160.
91. Tutt A, Robson M, Garber JE et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010;376:235-244.
92. Lu Y, Bellgrau D, Dwyer-Nield LD et al. Mutation-selective tumor remission with Rastargeted, whole yeast-based immunotherapy. Cancer Res 2004;64:5084-5088.
93. D'Angelo S, Park B, Krug L et al. Immunogenicity of GI-4000 vaccine in adjuvant consolidation therapy following definitive treatment in patients with stage I-III adenocarcinoma of the lung with g12c, g12d, or g12v kras mutations. J Clin Oncol 2011;29:7070a.
94. Muscarella P, Wilfong LS, Ross SB et al. A randomized, placebo-controlled, double blind, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gem versus gem alone in patients with resected pancreas cancer with activating ras mutations/survival and immunology analysis of the r1subgroup. J Clin Oncol 2012;30(suppl):e14501.
95. Strong JE, Coffey MC, Tang D et al. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17:3351-3362.
96. Hirano S, Etoh T, Okunaga R et al. Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model. Oncol Rep 2009;21:1381-1384.
97. Adair RA, Roulstone V, Scott KJ et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012;4:138ra177.
98. Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors. Diagnosticutility and clinical applications. Am J Clin Pathol 1999;112 (Suppl 1):S68-S75.
99. Bernhardt SL, Gjertsen MK, Trachsel S et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer 2006;95:1474-1482.
100. Middleton GW, Valle JW, Wedsley J et al. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol 2013;31(suppl): LBA4004a.
101. Le D, Gilliam AW, Picozzi V et al. Safety, efficacy, and immune analyses of a phase 2, randomized study of gvax pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer. Eur J Cancer 2013;49(suppl 2):S616.
102. Le DT, Brockstedt DG, Nir-Paz R et al. A liveattenuated Listeria vaccine (ANZ-100) and a liveattenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res 2012; 18:858-868.
103. Wolpin BM, O'Reilly EM, Ko YJ et al. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus ags-1c4d4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol 2013;24:1792-1801.
104. Ocean AJ, Pennington KL, Guarino MJ et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer 2012;118:5497-5506.
105. Beatty GL, Torigian DA, Chiorean EG et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013;19:6286-6295.
106. Beatty GL, Chiorean EG, Fishman MP et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011;331:1612-1616.
107. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-723.
108. Royal RE, Levy C, Turner K et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010;33:828-833.
109. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
110. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 anti-body in cancer. N Engl J Med 2012;366:2443-2454.
111. Chmielewski M, Hahn O, Rappl G et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012; 143:1095-1107.
112. García-Manteiga J, Molina-Arcas M, Casado FJ et al. Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003;9:5000-5008.
113. Giovannetti E, Del Tacca M, Mey V et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 2006;66:3928-3935.
114. Nakano Y, Tanno S, Koizumi K et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 2007; 96:457-463.
115. Poplin E, Wasan H, Rolfe L et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: Including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013;31:4453-4461.
116. Farrell JJ, Elsaleh H, Garcia M et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 2009;136:187-195.
117. Greenhalf W, Ghaneh P, Neoptolemos JP et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst 2014;106:djt347.
118. Boeck SH, Jung A, Laubender RP et al. Molecular markers of the egfr pathway in erlotinib-treated patients with advanced pancreatic cancer (apc): Translational analyses of a randomized, cross-over aio phase III trial. J Clin Oncol 2011;29(suppl):4047a.
119. Shroff RT, Javle MM, Li D et al. Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type-1 receptor (igf-1r) targeted therapy in pancreatic cancer. J Clin Oncol 2011;29(suppl):4052a.
120. Sangar V, Ricigliano M, O'Reilly EM et al. Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance. J Clin Oncol 2012;30(Suppl 34): 142a.
121. Goncalves A, Viret F, François E et al. BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer. J Clin Oncol 2011;29(suppl):4028a.
122. Deplanque G, Demarchi M, Hebbar M et al. Masitinib in nonresectable pancratic cancer: Results of a phase III randomized placebo-controlled trial. J Clin Oncol 2012;30(Suppl 34):158a.
123. Infante JR, Somer BG, Park JO et al. A randomized, double-blind, placebo-controlled trial of trametinib, a mek inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. J Clin Oncol 2012; 30(Suppl 34):291a.